Evidence map›Paper›PMID 34763601›Full record

ArticleCell cycle (Georgetown, Tex.)2021

TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin.

Anna Maria Lena, Erica Foffi, Massimiliano Agostini, Mara Mancini, Margherita Annicchiarico-Petruzzelli, Daniel Aberdam, Tania Velletri, Yufang Shi, Gerry Melino, Ying Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna Maria LenaDepartment of Experimental Medicine, TOR, University of Rome "Tor Vergata", Rome, Italy.
Erica FoffiDepartment of Experimental Medicine, TOR, University of Rome "Tor Vergata", Rome, Italy.
Massimiliano AgostiniDepartment of Experimental Medicine, TOR, University of Rome "Tor Vergata", Rome, Italy.ORCID 0000-0003-3124-2072
Mara ManciniIDI-IRCCS, Via dei Monti di Creta, Rome, IT.ORCID 0000-0001-5173-4854
Margherita Annicchiarico-PetruzzelliIDI-IRCCS, Via dei Monti di Creta, Rome, IT.
Daniel AberdamUniversity of Paris and INSERMU1138.
Tania VelletriCogentech Società Benefit Srl, Parco Scientifico E Tecnologico Della Sicilia, Catania, Italy.
Yufang ShiCas Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Gerry MelinoDepartment of Experimental Medicine, TOR, University of Rome "Tor Vergata", Rome, Italy.ORCID 0000-0001-9428-5972
Ying WangCas Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Eleonora CandiDepartment of Experimental Medicine, TOR, University of Rome "Tor Vergata", Rome, Italy.ORCID 0000-0001-8332-4825

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abbreviationsMSC, mesenchymal stem cells; OPG, osteoprotegerin; RUNX2, Run-trelated transcription factor 2.

Indexed as

Mesenchymal Stem CellsOsteoprotegerinBone RemodelingCell DifferentiationOsteogenesisOsteoprotegerinbreastmesenchymal stem cellsosteogenic differentiationp53 familyP63prostate cancer

Identifiers

PMID34763601
PMCPMC8794505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.